NIPT Reference Standard

HRD Reference Standards – For Homologous Recombination Deficiency Research

Well-characterized HRD reference samples with defined genomic scarring metrics (LOH, TAI, LST).

Home HRD Reference Standard

Product Center

0 evaluate

CBP90023

CBP90023

Inquire
0 evaluate

CBP90040

CBP90040

Inquire
0 evaluate

CBP90044

CBP90044

Inquire
tupian2

Product Introduce

Homologous Recombination Deficiency (HRD) Reference Standards

Homologous recombination deficiency (HRD) results from loss of function in the HRR pathway, most commonly due to BRCA1/2 mutations or other HRR gene alterations. HRD leads to characteristic “genomic scars” including loss of heterozygosity (LOH), telomeric allelic imbalance (TAI), and large-scale state transitions (LST). Tumors with HRD are more sensitive to PARP inhibitors and platinum-based therapies.

CB-Gene’s HRD reference standards were developed in response to the growing need for well-characterized controls in the HRD testing field. Starting in 2020, we collaborated with multiple diagnostic companies to benchmark samples and address the significant variability observed in HRD score calculations across different platforms and bioinformatics pipelines.

Our HRD reference panel includes:

22 paired tumor-normal samples (normal cells immortalized to preserve genomic integrity)

4 single samples (tumor-only)

1 sample that serves as both a paired and single sample for cross-validation

Samples classified as HRD Score-High, HRD Score-Medium, and HRD Score-Low based on multi-lab consensus data.

For Research Use Only. Not for use in diagnostic procedures. Not intended to replace national reference panels for regulatory submission.

Product Advantages

Our HRD Reference Standards to ensure the accuracy and reproducibility of HRD testing in clinical diagnostics and research, standardized reference materials are essential.

Paired immortalized cell lines

Tumor and matched normal cells immortalized to preserve genomic integrity and enable accurate somatic mutation calling.

WGS + dual-sample validation

Values determined through whole-genome sequencing with a paired analysis process to verify panel accuracy.

Multiple customizable formats

Includes Benign, Likely Benign, Uncertain Significance, Likely Pathogenic, and Pathogenic variants.

Authentic HRD-positive genomic characteristics

Includes pathogenic BRCA1/2 variants (germline and somatic), genome-wide LOH, TAI, and LST.

Wide HRD score distribution

Covers high, medium, and low HRD scores to simulate real clinical sample diversity.

Dedicated technical support

Free pre- and post-sales assistance for assay integration and data interpretation.

Application

Company Advantage

Expertise in reference standards – CB-Gene specializes in oncology molecular diagnostics with ISO‑certified production and patented technology.

Scientific Quality Management

With our ISO9001 certification, we adhere to a stringent quality management system, ensuring that all our products meet the highest standards of accuracy, stability, and consistency.

Experienced and Skilled Team

Backed by a talented team of experts, we leverage advanced technology and extensive experience to drive innovation in molecular diagnostics, ensuring we stay at the forefront of the industry.

Comprehensive annotation

Includes benign to pathogenic variants, helping you evaluate real‑world assay performance.

Comprehensive Product Range

We offer a complete set of reference materials, including SNP, Indel, CNV, Fusion, NIPT, and more, covering a wide array of diagnostic needs and offering customized services for a variety of applications.

tupian7

Contact Us

We're here to assist you! Whether you have questions about our products, services, or need technical support, our team is ready to provide you with the information you need. Reach out to us today!

FAQs

Q: What HRD metrics are included in the standards?
Our standards include all three classic genomic scar metrics: LOH (loss of heterozygosity) , TAI (telomeric allelic imbalance) , and LST (large-scale state transitions) , plus pathogenic BRCA1/2 variants (both germline and somatic) and a combined HRD score.
Q: What formats are available for the HRD standards?
We offer gDNA (genomic DNA) , FFPE (formalin-fixed paraffin-embedded) sections, and ctDNA (circulating tumor DNA) formats. Customization is also available upon request.
Q: How were the HRD scores determined?
Values are determined through whole-genome sequencing (WGS) with a dual-sample (tumor + normal) analysis process. This gold-standard approach ensures accuracy and allows users to verify their panel results against WGS data.
Q: Can I request a free trial sample?
Yes, CB-Gene welcomes researchers to apply for free trial samples of our HRD reference standards. Please contact our team at sales@cb-gene.com to apply.
Q: How can I request a quote or technical datasheet?
Please contact us at sales@cb-gene.com or visit our website. We offer free technical consultation, sample applications, and custom‑sized packaging.

Related Blogs

[Blogs]

TF IHC Quality Controls for Targeted Therapy and Companion Diagnostics

Cobioer Gene provides combined positive and negative TF (Tissue Factor) IHC controls in two formats: FFPE tissue blocks and pre-cut FFPE control slides. The controls are validated by immunohistochemistry for routine quality control of TF IHC assays and companion diagnostic assay development. For Research Use Only.

Read More
[Blogs]

PSMA IHC FFPE Controls: Paraffin Blocks vs. Pre-Cut Slides

The format of an IHC control can influence how easily a laboratory develops, validates, and monitors a PSMA staining workflow. While both paraffin blocks and pre-cut slides can be used as FFPE control materials, they support different laboratory needs.

Read More
[Blogs]

PSMA IHC Positive and Negative 2-in-1 FFPE Control Standards

Reliable immunohistochemistry depends on more than selecting an antibody against the correct target. Laboratories also need appropriate control materials to evaluate whether the staining result is specific, interpretable, and reproducible.

Read More
[Blogs]

ATP7B Reference Standards for Multi-Platform Wilson Disease Assay Validation

For laboratories developing and validating genetic tests for Wilson disease (WD), selecting appropriate ATP7B reference standards is an important part of establishing a controlled and reproducible assay. Wilson disease testing may use Sanger sequencing, quantitative real-time PCR (qPCR), droplet digital PCR (ddPCR), or targeted next-generation sequencing (NGS). Each workflow requires well-characterized genomic DNA reference materials to evaluate analytical performance, monitor run-to-run consistency, and support reliable ATP7B variant detection and genotyping. Suitable ATP7B reference standards should have clearly defined genotypes and variant identities, a relevant sample matrix, compatibility with the intended method, and characteristics aligned with the laboratory's validation plan. This article reviews the principal considerations when selecting ATP7B reference standards for multi-platform Wilson disease assay validation.

Read More
tupian8

Get Touch With Us

Contact Us
tupian9

Contact Info

Have questions or need assistance? We're here to help! Reach out to our team, and we'll provide the support you need.

Copyright © 2025 Nanjing CB-Gene Biotechnology Co., Ltd. Sitemap. Privacy Policy